Boston Scientific Corporation (BSX)财务
NYSE · Healthcare · Medical - Devices · 员工59,000人 · CEO Michael F. Mahoney
- 股价
- $41.98 -1.66%
- 市值
- $608亿
- 企业价值
- $729亿
- 最近财报
- Q3 '26 2026-09-30提交
- 下次财报
- 2027-02-03 EPS预期 $0.79
营收(TTM)$211亿+8.9% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)21.0%+3.7 百分点 对比去年同期营业利润 $44.4亿
净利润(TTM)$34.9亿+25.2% 对比去年同期税后,含营业外收益
自由现金流(TTM)–– 对比去年同期资本支出 –
稀释EPS(TTM)$2.36+26.8% 对比去年同期最近4个季度之和
净现金-$121亿-5.2% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $608亿 EV $729亿
- 营收
- $211亿 过去12个月
- 营收增速
- +5% FY2026年一致预期
- 净利润率
- 16.6% 净利润 / 营收,TTM
- P/E
- 17.7× 预期 13.2×(FY2026)
- P/S
- 2.9× 股价 / 营收,TTM
- EV / EBITDA
- 13.5× TTM
- 自由现金流
- – 过去12个月
- 净利润
- $34.9亿 过去12个月
- 营收预期
- $210亿 FY2026年一致预期
- 盈利
- 2027-02-03 营收预期 $52亿
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-28):营收超预期1.0%,EPS 符合预期营收$51.4亿,预期$50.9亿(+1.0%);EPS $0.73,预期$0.73(+0.4%)。
- 营收增长放缓:同比1.4%Q3 '26营收$51.4亿,此前四个季度的平均值为13.8%。
- 营业利润率21.0%(TTM),较去年同期+3.7 百分点营收增长8.9%,营业利润增长32.2%。
- 税前利润的21.3%被营业外亏损吞噬税前利润$36.6亿,营业利润$44.4亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 稀释股数一年内减少2.9%Q3 '26稀释股数14.5亿,一年前为15亿。
- 净债务 $121亿现金 + 短期投资 $5.39亿,含租赁债务 $126亿;一年前净债务 $115亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $51.4亿 | $50.7亿 | +1.4% |
| 毛利率 | 66.7% | 69.9% | -3.2 百分点 |
| 营业利润 | $9.79亿 | $10.5亿 | -6.8% |
| 营业利润率 | 19.1% | 20.7% | -1.7 百分点 |
| 净利润 | $5.78亿 | $7.55亿 | -23.4% |
| 稀释EPS | $0.40 | $0.50 | -20.0% |
| 经营现金流 | – | $13.4亿 | – |
| 资本支出 | – | $1.81亿 | – |
| 自由现金流 | – | $11.6亿 | – |
| R&D | $5.2亿 | $5.14亿 | +1.2% |
| 股权激励费用 | – | $7900万 | – |
实际 vs 一致预期
2026-10-28| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $51.4亿 | $50.9亿 | +1.0% |
| EPS(一致预期口径) | $0.73 | $0.73 | +0.4% |
来自2026-10-28发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Cardiovascular | $36.2亿 | +8.3% | 66.6% | – | – | |
| MedSurg | $18.2亿 | +5.9% | 33.4% | – | – |
按地区划分的营收
占总额比例| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $6.06亿 | -70.3% | 23.1% | – | – | |
| Non-US | $20.2亿 | +9.8% | 76.9% | – | – |
分部利润
取自每份10-Q / 10-K分部附注的各披露分部营业利润(多数数据源缺少的利润拆分)。
Q3 '24分部
| 分部 | 营收 | 同比 | 营业利润 | 同比 | 利润率 | 去年同期利润率 | TTM营业利润 |
|---|---|---|---|---|---|---|---|
| Total Allocated To Reportable Segments | – | – | $13.5亿 | – | – | – | – |
各分部营业利润
季度各分部营业利润率
季度利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 自由现金流
- –
- 股东回报 / FCF
- –
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 17.7× | 67.5× | 48.6× – 103.1× |
| EV / EBITDA | 13.5× | 29.4× | 26.8× – 36.1× |
| EV / 营收 | 3.5× | 6.8× | 5.7× – 8.5× |
| 股价 / FCF | 16.8× | 51.2× | 38.6× – 72.4× |
| 股价 / 净资产 | 2.4× | 4.7× | 3.6× – 6.0× |
| FCF收益率 | 6.0% | 2.0% | 1.4% – 2.6% |
| 投入资本回报率 | 10.5% | 6.2% | 3.9% – 8.8% |
| 净资产收益率 | 14.2% | 7.8% | 4.0% – 11.9% |
分析师
一致目标价 $54.65 (+30.2%)
区间 $46.00 – $71.00 · 评级 Buy
强烈买入1
买入33
持有10
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $210亿 | +4.7% | $3.18 | +64.1% | 13.2× | 16 |
| FY2027 | $210亿 | +0.1% | $3.17 | -0.4% | 13.2× | 17 |
| FY2028 | $222亿 | +5.3% | $3.40 | +7.3% | 12.3× | 10 |
| FY2029 | $235亿 | +6.1% | $3.73 | +9.6% | 11.3× | 4 |
| FY2030 | $256亿 | +8.7% | $4.01 | +7.6% | 10.5× | 4 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Boston Scientific Corporation在近期10-Q / 10-K文件中标记的全部346项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts and Financing Receivable, after Allowance for Credit Loss, Current | $30.5亿 | $28.2亿 | +8.3% | $29.3亿 | $25.6亿 | +14.4% |
| Accounts Payable, Current | $12.3亿 | $9.62亿 | +28.0% | $11.4亿 | $9.6亿 | +19.2% |
| Accounts Receivable, Allowance for Credit Loss | $1.32亿2025-12-31 | $1.09亿 | +21.1% | $1.32亿 | $1.09亿 | +21.1% |
| Accounts Receivable, Allowance for Credit Loss, Current | $1.35亿 | $1.12亿 | +20.5% | $1.32亿 | $1.09亿 | +21.1% |
| Accounts Receivable, Allowance for Credit Loss, Writeoff | – | – | – | $3300万 | $4300万 | -23.3% |
| Accounts Receivable, before Allowance for Credit Loss, Current | $31.8亿 | $29.3亿 | +8.8% | $30.6亿 | $26.7亿 | +14.7% |
| Accounts Receivable, Credit Loss Expense (Reversal) | – | – | – | $5600万 | $4100万 | +36.6% |
| Accrued Income Taxes, Noncurrent | $4.03亿2025-09-30 | $3.64亿 | +10.7% | $3.57亿2024-12-31 | $4.7亿 | -24.0% |
| Accrued Liabilities, Current | $27.6亿 | $28亿 | -1.5% | $32亿 | $27.7亿 | +15.4% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $37.3亿 | $37.8亿 | -1.5% | $36.1亿 | $35.3亿 | +2.2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$3.04亿 | -$7.22亿 | +57.9% | -$6.1亿 | $2.75亿 | -321.8% |
| Additional Paid in Capital, Common Stock | $217亿 | $212亿 | +2.3% | $215亿 | $211亿 | +2.1% |
| Amortization of Intangible Assets | $2.33亿 | $2.25亿 | +3.6% | $8.97亿 | $8.56亿 | +4.8% |
| Assets | $452亿 | $416亿 | +8.8% | $437亿 | $394亿 | +10.9% |
| Assets, Current | $79.7亿 | $71.2亿 | +12.0% | $87.9亿 | $69.2亿 | +27.1% |
| Assets, Fair Value Disclosure | $4.75亿 | – | – | – | – | – |
| Buildings and Improvements, Gross | $27.2亿 | $21.5亿 | +26.2% | $24.8亿 | $20.2亿 | +23.0% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | -$1600万 | -$500万 | -220.0% | $1800万 | -$500万 | +460.0% |
| Business Combination, Contingent Consideration, Liability | $2.57亿 | $3.67亿 | -30.0% | $3.85亿 | $1.71亿 | +125.1% |
| Business Combination, Contingent Consideration, Liability, Current | $7800万2025-09-30 | $6200万 | +25.8% | $6300万2024-12-31 | $3.04亿 | -79.3% |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $3.01亿2025-09-30 | $1.09亿 | +176.1% | $1.08亿2024-12-31 | $1亿 | +8.0% |
| Cash | $4.09亿 | $3.88亿 | +5.4% | $9.65亿 | $3.64亿 | +165.1% |
| Cash and Cash Equivalents, at Carrying Value | $5.39亿 | $5.34亿 | +0.9% | $19.7亿 | $4.14亿 | +374.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $7.53亿 | $7.41亿 | +1.6% | $21.5亿 | $6.06亿 | +254.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$8.9亿 | -$1.79亿 | -397.2% | $15.4亿 | -$4.5亿 | +442.4% |
| Common Stock, Capital Shares Reserved for Future Issuance | 1.32亿2025-12-31 | 1.39亿 | -5.0% | 1.32亿 | 1.39亿 | -5.0% |
| Common Stock, Par or Stated Value Per Share | $0.01 | $0.01 | 0.0% | $0.01 | $0.01 | 0.0% |
| Common Stock, Shares Authorized | 20亿 | 20亿 | 0.0% | 20亿 | 20亿 | 0.0% |
| Common Stock, Shares, Issued | 17.5亿 | 17.4亿 | +0.4% | 17.5亿 | 17.4亿 | +0.5% |
| Common Stock, Value, Issued | $1700万 | $1700万 | 0.0% | $1700万 | $1700万 | 0.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $200万 | $100万 | +100.0% | $600万 | -$1500万 | +140.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $10亿 | $1.03亿 | +870.9% | $20.1亿 | $20.8亿 | -3.2% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $10亿 | $1.04亿 | +863.5% | $20.2亿 | $20.6亿 | -2.1% |
| Construction in Progress, Gross | $9.11亿 | $10.4亿 | -12.5% | $11.6亿 | $10.4亿 | +12.2% |
| Contract with Customer, Liability | $6.91亿 | $6.62亿 | +4.4% | $6.82亿 | $6.35亿 | +7.4% |
| Contract with Customer, Liability, Revenue Recognized | $6300万2025-12-31 | $5400万 | +16.7% | $2.64亿 | $2.31亿 | +14.3% |
| Cost of Goods and Services Sold | $15.9亿 | $16.4亿 | -2.6% | $62.2亿 | $52.6亿 | +18.3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $2.42亿 | $3.1亿 | -21.9% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $2.41亿 | $1.84亿 | +31.0% |
| Current Income Tax Expense (Benefit) | – | – | – | $5.05亿 | $5.26亿 | -4.0% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $2200万 | $3100万 | -29.0% |
| Debt and Lease Obligation | $116亿2025-09-30 | $109亿 | +6.6% | $107亿2024-12-31 | $91亿 | +18.1% |
| Debt Instrument, Fair Value Disclosure | $123亿 | $113亿 | +8.4% | $112亿 | $103亿 | +8.0% |
| Debt, Current | $17.1亿 | $4.8亿 | +256.0% | $2.99亿 | $17.8亿 | -83.2% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$6600万 | -$1.31亿 | +49.6% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $1.07亿 | $9200万 | +16.3% |
| Deferred Income Tax Assets, Net | $39.1亿 | $37.8亿 | +3.5% | $36.8亿 | $36.6亿 | +0.5% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$1200万 | -$9000万 | +86.7% |
| Deferred Income Tax Liabilities, Net | $2.21亿 | $2.26亿 | -2.2% | $2.2亿 | $1.55亿 | +41.9% |
| Deferred Revenue | $3.59亿2025-09-30 | $3.28亿 | +9.5% | $3.29亿2024-12-31 | $3.11亿 | +5.8% |
| Deferred Revenue, Current | $3.13亿2025-12-31 | $3.06亿 | +2.3% | $3.13亿 | $3.06亿 | +2.3% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$5300万 | -$5200万 | -1.9% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $29亿2025-12-31 | $30.6亿 | -5.3% | $29亿 | $30.6亿 | -5.3% |
| Deferred Tax Assets, Gross | $48.6亿2025-12-31 | $49.9亿 | -2.7% | $48.6亿 | $49.9亿 | -2.7% |
| Deferred Tax Assets, in Process Research and Development | $3.36亿2025-12-31 | $3.29亿 | +2.1% | $3.36亿 | $3.29亿 | +2.1% |
| Deferred Tax Assets, Inventory | $5200万2025-12-31 | $1500万 | +246.7% | $5200万 | $1500万 | +246.7% |
| Deferred Tax Assets, Net | $34.6亿2025-12-31 | $35亿 | -1.3% | $34.6亿 | $35亿 | -1.3% |
| Deferred Tax Assets, Net of Valuation Allowance | $36.6亿2025-12-31 | $37.2亿 | -1.8% | $36.6亿 | $37.2亿 | -1.8% |
| Deferred Tax Assets, Operating Loss Carryforwards | $6.26亿2025-12-31 | $7.74亿 | -19.1% | $6.26亿 | $7.74亿 | -19.1% |
| Deferred Tax Assets, Operating Loss Carryforwards, Domestic | $5.29亿2025-12-31 | $5.58亿 | -5.2% | $5.29亿 | $5.58亿 | -5.2% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-01